Filing Details

Accession Number:
0001209191-23-053487
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-10-24 17:22:48
Reporting Period:
2023-10-23
Accepted Time:
2023-10-24 17:22:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1515673 Ultragenyx Pharmaceutical Inc. RARE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1303811 Richard Thomas Kassberg C/O Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato CA 94949
Cbo & Evp No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-10-23 39,878 $6.86 286,738 No 4 M Direct
Common Stock Disposition 2023-10-23 39,878 $32.78 246,860 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-10-23 39,878 $0.00 39,878 $6.86
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2023-10-31 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.09 to $33.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  2. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
  3. The option vested with respect to 1/4th of the shares on the first anniversary of the grant date of the option and 1/48th of the shares thereafter such that the option fully vested on the fourth anniversary of the grant date.